Hemophilia A Factor VIII Deficiency

Slide 1 · Hemophilia A

Factor VIII deficiency

Mechanism • Inheritance • Bleeding phenotype • Diagnosis

Pathology lecture

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Explain why factor VIII deficiency impairs secondary hemostasis.

Connect X-linked inheritance and F8 mutations with clinical severity.

Recognize hemarthrosis and deep-tissue bleeding patterns.

Interpret the PT, PTT, and factor VIII-specific assay results.

Relate replacement, bypass therapy, and inhibitors to mechanism.

Slide 3 · Hemophilia A: Core definition

An inherited factor VIII defect that compromises the factor IXa–VIIIa complex and causes potentially life-threatening bleeding.

Usually inherited in an X-linked recessive pattern.

Residual functional factor VIII activity largely determines severity.

Slide 4 · Where hemophilia A fits among bleeding disorders

Defective primary hemostasis

Platelet number or function is abnormal.

Typical bleeding is mucocutaneous.

Petechiae or small skin hemorrhages are characteristic.

Defective secondary hemostasis

Coagulation factor activity is deficient.

Bleeding commonly occurs in deep tissues and joints.

Hemophilia A is a prototype of this pattern.

Slide 5 · The phases of normal hemostasis

Vascular response

Transient vasoconstriction after injury

Platelet plug

Adhesion, activation and aggregation

Fibrin generation

Coagulation stabilizes the plug

Clot remodeling

Stabilization followed by resorption

Factor VIII acts in the fibrin-generating, secondary-hemostasis phase.

Slide 6 · Primary hemostasis: The initial platelet plug

Endothelial disruption exposes subendothelial collagen and vWF.

Platelet GpIb binds vWF to support initial adhesion.

Platelet activation changes shape and recruits further platelets.

GpIIb/IIIa and fibrinogen support platelet aggregation.

Slide 7 · Secondary hemostasis: Stabilization by fibrin

Injury exposes TF

Tissue factor activates factor VII

Protease cascade

Coagulation reactions amplify

Thrombin forms

Prothrombin is converted to thrombin

Fibrin deposited

Fibrin reinforces the platelet plug

An initially formed platelet plug is not sufficient for stable hemostasis.

Slide 8 · Two hemostatic defects; Two clinical signatures

Platelet / vWF defect

Small-vessel skin or mucosal bleeding; Petechiae, purpura, epistaxis.

Coagulation factor defect

Soft-tissue hematoma, hemarthrosis, or prolonged postsurgical bleeding.

Why this matters

A bleeding pattern provides an early clue to the defective hemostatic component.

Slide 9 · The coagulation cascade is assembled on surfaces

Activated clotting factors are enzymes acting on substrate proteins.

Nonenzymatic cofactors accelerate specific proteolytic reactions.

Activated platelets provide negatively charged phospholipid surfaces.

Calcium contributes to assembly of membrane-bound complexes.

Slide 10 · Factor VIIIa is a cofactor—not the protease

Factor IXa

Active protease: The enzyme

Factor VIIIa

Reaction accelerator: The cofactor

Factor X

Substrate that becomes Xa

The assembled IXa–VIIIa complex promotes conversion of factor X to factor Xa.

Slide 11 · Surface organization of the factor X–activating complex

Activated platelet

Exposes a procoagulant phospholipid surface

Ca²⁺

Helps assemble coagulation components

IXa + VIIIa + X

Membrane-localized enzyme–cofactor–substrate complex

Correct assembly increases efficiency of factor X activation.

Slide 12 · The major in-vivo route into factor IX activation

Tissue factor exposed

Vascular wall injury

VIIa–TF complex

Initiates physiologic coagulation

Factor IX activation

Generates IXa

IXa with VIIIa

Promotes X → Xa

The in-vivo pathway is not identical to the isolated laboratory “intrinsic” pathway.

Slide 13 · Downstream consequence of factor X activation

IXa + VIIIa

Factor X–activating complex

Factor Xa

Converts prothrombin via Va-dependent complex

Thrombin

Cleaves fibrinogen

Fibrin network

Stabilizes the hemostatic plug

Deficient VIIIa reduces propagation of coagulation toward an effective fibrin clot.

Slide 14 · Why factor VIII deficiency can cause major bleeding

The factor IXa–VIIIa complex is a principal activator of factor X during coagulation in vivo.

A deficiency in a cofactor can be as consequential as loss of a protease.

This explains why isolated factor VIII deficiency disrupts clot stabilization.

Slide 15 · Laboratory cascade versus physiology

In laboratory assays

PT measures the tissue-factor-initiated testing pathway.

PTT interrogates the contact-activated testing pathway.

These are functional plasma tests.

In living vessels

Tissue factor is the major trigger.

The IXa–VIIIa complex is central for factor X activation.

Laboratory pathway labels are useful but incomplete models.

Slide 16 · Factor VIII travels in plasma with vWF

Factor VIII secreted

Circulating coagulation cofactor

VWF binds VIII

Complex forms in blood

VIII protected

Binding stabilizes factor VIII

VIII functions

Cofactor in IXa-mediated X activation

VWF is a carrier and stabilizer of factor VIII, not its replacement in the coagulation reaction.

Slide 17 · VWF binding prolongs factor VIII survival

A factor VIII half-life of approximately 2.4 hours without vWF stabilization versus 12 hours when bound to vWF.

Loss of vWF may secondarily reduce circulating factor VIII.

This helps explain how von Willebrand disease can affect both platelet function and PTT.

Slide 18 · The vWF–factor VIII complex has two distinct roles

VWF: Platelet adhesion

Subendothelial vWF can anchor platelets through GpIb.

VWF connects injury-exposed matrix with platelets.

Deficiency may cause mucocutaneous bleeding.

Factor VIII: Coagulation

VIIIa supports IXa-driven factor X activation.

Adequate factor VIII promotes fibrin formation.

Deficiency produces a deep-tissue bleeding phenotype.

Slide 19 · The defect in hemophilia A is specific

Factor VIII

Missing or dysfunctional cofactor for factor IXa.

Factor IX

Its role as protease is preserved if there is no independent deficiency.

VWF

Carrier protein is not the primary inherited lesion in hemophilia A.

Functional result

Inefficient X activation and inadequate secondary hemostasis.

Slide 20 · Hemophilia A is caused by F8 gene mutations

Pathogenic alterations affecting the factor VIII gene reduce the amount or activity of functional factor VIII.

The factor VIII gene lies on the X chromosome.

Different mutations yield different residual factor VIII activities.

Slide 21 · X-linked recessive inheritance

Pathogenic F8 allele

Located on the X chromosome

One X chromosome

Most males have no second F8 allele

Functional deficiency

A single pathogenic allele can produce disease

Hemophilia A mainly affects males, but symptomatic females also occur.

Slide 22 · What a family history can reveal

An affected male commonly has disease because his single F8 allele is pathogenic.

Heterozygous females may transmit the altered X chromosome.

Pedigree information supports—but does not establish—the diagnosis.

A negative family history cannot exclude hemophilia A.

Slide 23 · Carrier mother × unaffected father

Illustrative X-linked transmission: Maternal Xᴺ / Xᴴ and paternal Xᴺ / Y

Xᴺ / Xᴺ

Unaffected daughter

Xᴴ / Xᴺ

Carrier daughter

Xᴺ / Y

Unaffected son

Xᴴ / Y

Affected son

Punnett square is a Mendelian educational inference, not patient-specific risk prediction.

Slide 24 · Affected father × unaffected noncarrier mother

Illustrative X-linked transmission: Paternal Xᴴ / Y and maternal Xᴺ / Xᴺ

Xᴴ / Xᴺ

Carrier daughter

Xᴴ / Xᴺ

Carrier daughter

Xᴺ / Y

Unaffected son

Xᴺ / Y

Unaffected son

An affected father passes his X to daughters and his Y to sons.

Slide 25 · How can a female have hemophilia A?

Homozygosity for pathogenic F8 alleles can produce disease.

Some heterozygous females experience excessive bleeding.

Hemophilia A should not be considered categorically impossible in females.

Clinical phenotype and factor VIII activity remain decisive.

Slide 26 · Unfavorable lyonization in a heterozygous female

Two X alleles

One normal, one pathogenic

X inactivation

Normally mosaic across cells

Unfavorable skew

Normal F8-bearing X inactive in many cells

Low VIII activity

Bleeding phenotype can emerge

Skewed X inactivation is the explanation proposed by Robbins for some symptomatic carriers.

Slide 27 · A negative family history is common enough to matter

That approximately 30% of affected patients lack a family history and attributes their disorder to new mutations.

Absence of affected relatives cannot rule out a congenital factor defect.

Evaluation must rely on the phenotype and confirmatory factor VIII testing.

Slide 28 · Allelic heterogeneity creates a severity spectrum

Many different F8 mutations can cause hemophilia A.

Some variants abolish production of factor VIII.

Other mutations allow protein production but reduce its function.

Variants preserving some active protein are associated with milder disease.

Slide 29 · A severe mechanism: X-chromosomal inversion

Chromosomal inversion

Disrupts F8 gene function

Factor VIII synthesis

Can be completely abolished

FVIII activity

Profoundly deficient

Clinical disease

Severe bleeding phenotype

The text associates its most severe deficiencies with inversions abolishing factor VIII synthesis.

Slide 30 · A different mechanism: Nonfunctional factor VIII

Point mutation

Changes factor VIII protein

Protein produced

Immunologic assay may detect it

Biologic activity lost

IXa cofactor function is impaired

Bleeding persists

Quantitative antigen result can mislead

The amount of protein detected does not always equal functional activity.

Slide 31 · Antigen level is not equivalent to cofactor function

Immunologic measurement

Detects the amount of factor VIII protein.

A point-mutant protein may be present.

Normal antigen does not guarantee normal hemostasis.

Functional activity assay

Measures clotting activity attributable to factor VIII.

Identifies functional cofactor deficiency.

Needed to establish hemophilia A in the proper context.

Slide 32 · Residual factor VIII activity determines phenotype

F8 genotype

Inversion, point variant, or other defect

Functional protein

Absent, dysfunctional, or partly retained

Measured activity

Degree of factor VIII deficiency

Clinical severity

Bleeding correlates with functional activity

Severity cannot be inferred from gene status alone without functional information.

Slide 33 · Robbins classification by factor VIII activity

Severe

< 1% of normal

Marked tendency to major bleeding

Moderately severe

2–5% of normal

Intermediate clinical severity

Mild

6–50% of normal

Bleeding may become evident with hemostatic challenge

Slide 34 · The severity scale is a continuum

Lower factor VIII activity generally predicts more severe bleeding.

Not every patient has the same mutation or residual cofactor activity.

Mild deficiency may remain clinically silent until a bleeding challenge.

Activity measurement supplies a quantitative disease descriptor.

Slide 35 · Severe hemophilia: Very low factor VIII activity

Severe disease is associated with factor VIII activity below 1% of normal in the supplied Robbins classification.

Spontaneous deep-tissue and joint bleeding may occur.

Trauma or surgery can precipitate major hemorrhage.

Slide 36 · Intermediate factor VIII deficiency

Robbins labels 2–5% activity as moderately severe disease.

Bleeding severity lies between the severe and mild phenotypes.

Clinical assessment must include previous spontaneous or injury-related bleeding.

Measured activity connects the presentation to the mutation’s functional effect.

Slide 37 · Mild hemophilia A still carries procedural risk

Robbins assigns 6–50% factor VIII activity to its mild category.

Patients may not recognize their disorder without a major challenge.

Dental work, trauma, or an operation can disclose an underlying deficiency.

A mild baseline phenotype does not imply normal hemostatic reserve.

Slide 38 · Trauma or surgery can expose a factor VIII defect

Tissue injury

Normal requirement for rapid clotting

Fibrin generation needed

Stable hemostatic plug

Factor VIII deficient

Insufficient secondary hemostasis

Persistent hemorrhage

Substantial or prolonged blood loss

The source highlights massive hemorrhage after trauma or surgery.

Slide 39 · A classic history: Prolonged bleeding after a procedure

Post-extraction or postsurgical bleeding suggests defective clot stabilization.

Blood loss may continue despite initial platelet adhesion and aggregation.

Repeated bleeding episodes support a significant coagulation factor defect.

The anatomic pattern helps distinguish factor deficiency from platelet dysfunction.

Slide 40 · Hemarthrosis is a defining clinical clue

Bleeding into a joint cavity is called hemarthrosis and is particularly characteristic of hemophilia.

Joints experience repeated minor mechanical stress.

Episodes may be described as spontaneous despite the absence of recognized trauma.

Slide 41 · Repeated hemarthroses drive disability

Joint hemorrhage

Blood collects within a joint

Recurrent bleeding

Repeated injury episodes

Progressive deformity

Joint damage accumulates

Functional disability

Movement and daily function impaired

Progressive disabling joint deformity as a complication.

Slide 42 · Deep muscle and soft-tissue hemorrhage

Secondary hemostatic defects predispose to deep soft-tissue bleeding.

A hematoma represents localized extravasation and accumulation of blood.

Muscle bleeding is an important part of the hemophilia phenotype.

Large bleeds may follow an apparently minor injury.

Slide 43 · Central nervous system bleeding is especially serious

The central nervous system is among the recognized sites of hemorrhage in severe coagulation-factor deficiencies.

Clinical consequences depend strongly on the site of the bleeding.

Neurologic bleeding represents a potentially fatal manifestation.

Slide 44 · Why joints and muscles? An unresolved question

The precise explanation for preferential hemorrhage into joints, muscles, and the central nervous system remains uncertain.

Common mechanical stress does not constitute a complete molecular explanation.

Do not claim a proven tissue-specific mechanism that the source does not provide.

Slide 45 · Bruising may be prominent, but interpret its pattern

Hemophilia A may produce easy bruising and large posttraumatic ecchymoses.

Deep hematomas are more suggestive than multiple pinpoint petechiae.

Bleeding following a procedure deserves attention even without joint involvement.

A characteristic phenotype guides, but cannot replace, laboratory testing.

Slide 46 · Petechiae are characteristically absent

Unlike many platelet disorders, hemophilia A usually does not produce petechiae.

Petechiae point toward small-vessel or primary hemostatic abnormalities.

The negative finding helps localize a suspected bleeding defect.

Slide 47 · Pattern recognition: Two patients who bleed

Patient with petechiae

Numerous small skin or mucosal hemorrhages.

Consider platelet number, platelet function, or vWF.

Use the clinical context to select confirmatory tests.

Patient with hemarthrosis

Deep joint bleeding following small stress or no clear trauma.

Consider an intrinsic-pathway coagulation factor defect.

Factor VIII and IX testing can distinguish common hemophilias.

Slide 48 · Characteristic screening profile

Hemophilia A usually shows a prolonged PTT with a normal PT.

This pattern points to a factor tested by the PTT assay.

Factor VIII-specific testing is still required for diagnosis.

Slide 49 · What does a prolonged PTT reflect?

PTT assesses factors XII, XI, IX, VIII, X, V, II, and fibrinogen.

Its initiation uses negatively charged surfaces, phospholipid, and calcium.

Deficient factor VIII delays in-vitro fibrin clot formation.

A prolonged PTT alone is not specific for hemophilia A.

Slide 50 · Why is PT often normal?

PT: Tested components

Assesses factor VII and the common-pathway factors.

Initiated with tissue factor in the laboratory.

Factor VIII is not the defining component of PT.

PTT: Tested components

Includes factor VIII and factor IX function.

Hemophilia A selectively affects a PTT-dependent reaction.

Normal PT plus prolonged PTT helps focus further investigation.

Slide 51 · From bleeding history to confirmation

Clinical pattern

Joint / muscle bleeding or procedural hemorrhage

Screening assays

PTT prolonged; PT usually normal

Factor assays

Measure factor VIII-specific activity

Interpretation

Correlation with severity and phenotype

Screening narrows the possibilities; The factor VIII-specific assay establishes the defect.

Slide 52 · A useful test hierarchy

PT and PTT

Show the pattern of abnormal coagulation; Do not specify the exact factor.

Factor VIII activity

Functional test required to diagnose and grade the deficiency.

Factor VIII antigen

Can be preserved despite loss of function in selected mutations.

Clinical correlation

Deep bleeding and inheritance reinforce the laboratory interpretation.

Slide 53 · Hemophilia A and hemophilia B

Hemophilia A

Deficiency of factor VIII cofactor.

PT normal; PTT prolonged.

Factor VIII activity assay identifies the defect.

Hemophilia B

Deficiency of factor IX protease.

Clinical phenotype can be indistinguishable.

Factor IX-specific assay identifies the defect.

Slide 54 · Hemophilia A versus von Willebrand disease

Hemophilia A

Primary molecular lesion involves factor VIII.

Dominant clinical clue: Deep-tissue and joint bleeding.

Factor VIII cofactor activity deficient.

Von Willebrand disease

Primary lesion involves vWF.

Mucocutaneous bleeding often dominates.

Factor VIII may fall because vWF normally stabilizes it.

Slide 55 · Inherited versus acquired factor deficiencies

Hemophilia A

Typically one inherited clotting factor is affected: Factor VIII.

Severe liver disease

Multiple factor deficiencies may occur from impaired synthesis.

Vitamin K deficiency

Affects synthesis of II, VII, IX, X and protein C.

DIC

Multiple factors are consumed during systemic coagulation activation.

Slide 56 · A disciplined diagnostic interpretation

Deep bleeding phenotype

Raises suspicion of a coagulation factor defect

Isolated PTT prolongation

Focuses laboratory investigation

Specific factor activity

Distinguishes VIII deficiency from IX deficiency

Genetics / context

Explains inheritance, severity and family variation

Neither bleeding pattern nor PTT prolongation alone identifies factor VIII deficiency.

Slide 57 · Pitfall: Normal antigen but deficient function

Some severe F8 point mutations produce measurable factor VIII protein.

An immunoassay may therefore appear reassuring.

Functional cofactor activity can remain profoundly abnormal.

Never equate normal antigen concentration with normal factor VIII activity.

Slide 58 · Pitfall: No affected relatives

About 30% of patients have no family history.

A de novo pathogenic F8 variant can account for an apparently sporadic case.

Carrier females may not have been recognized in a pedigree.

The diagnosis rests on clinical and functional laboratory evidence.

Slide 59 · Treatment principle: Replace the deficient cofactor

Factor VIII deficiency

Inadequate VIIIa-dependent X activation

Recombinant VIII infusion

Supplies functional cofactor

IXa–VIIIa complex

Factor X activation supported

Fibrin generation

Hemostatic potential restored

Recombinant factor VIII is a treatment approach.

Slide 60 · Bispecific antibody: Functional bypass

Bispecific antibody

Binds factor IXa and factor X

Targets brought together

Mimics essential bridging function

Factor VIII bypassed

Improves coagulation without VIII replacement

The antibody strategy remains useful even when anti-VIII inhibitors are present.

Slide 61 · Anti-factor VIII inhibitors complicate replacement

Inhibitory antibodies in about 15% of patients with severe hemophilia A treated with recombinant factor VIII.

These antibodies bind factor VIII and inhibit its action.

The risk creates a rationale for factor VIII-independent bypass therapy.

Slide 62 · Two treatments act at different points

Recombinant factor VIII

Directly supplies the deficient molecule.

Requires functional activity of infused factor VIII.

Inhibitory antibodies can prevent efficacy.

Bispecific antibody

Brings clotting factors into functional proximity.

Bypasses the requirement for factor VIII.

Can remain active with anti-factor VIII antibodies.

Slide 63 · A major limitation: Access and cost

The very high cost of both recombinant factor VIII and bispecific antibody therapy.

These costs complicate treatment access in low-resource settings.

Scientific efficacy and equitable availability are separate questions.

Slide 64 · Case discussion: Recurrent swollen knee

A young male develops episodes of painful knee swelling after minor activity; The history includes prolonged bleeding after dental extraction.

Which part of hemostasis is most likely impaired?

Recurrent hemarthrosis strongly suggests a secondary-hemostatic defect.

Factor VIII deficiency is one leading candidate, but not the only one.

PT, PTT, and factor-specific activity should clarify the diagnosis.

Slide 65 · Case discussion: An isolated prolonged PTT

A patient has easy bruising and intramuscular hematomas. PT is normal and PTT is prolonged.

Why is a factor VIII assay necessary?

The screening pattern suggests dysfunction in the PTT-tested factors.

Hemophilia A and hemophilia B may look identical clinically.

Functional factor VIII and IX assays distinguish the disorders.

Slide 66 · Case discussion: Symptomatic female carrier

A heterozygous female from a family with hemophilia has excessive procedural bleeding and low functional factor VIII activity.

Can heterozygosity produce clinically significant hemophilia?

Yes; Rare symptomatic heterozygous females.

Unfavorable X inactivation provides one proposed mechanism.

Measured factor VIII activity—not sex alone—determines clinical interpretation.

Slide 67 · Case discussion: Antigen–activity discordance

An affected patient has severe bleeding, with factor VIII protein detectable by immunoassay but markedly deficient coagulation activity.

What molecular explanation fits this discrepancy?

A dysfunctional factor VIII protein can be produced after a point mutation.

Antigen detection and factor function measure different properties.

Functional assay results best explain the bleeding phenotype.

Slide 68 · Putting the disease together

F8 mutation

Inherited or de novo

VIIIa dysfunction

Reduced IXa-mediated X activation

Impaired fibrin clot

Defective secondary hemostasis

Deep bleeding

Hemarthrosis and hematomas

Genotype → factor activity → coagulation failure → clinical phenotype.

Slide 69 · Clinical–laboratory correlation

Mechanism

Functional factor VIII is missing or defective.

Typical phenotype

Hemarthrosis, muscle hemorrhage and excessive posttraumatic bleeding.

Laboratory pattern

Prolonged PTT, normal PT; Confirm with factor VIII activity.

Treatment rationale

Replace factor VIII or bypass its function; Consider inhibitory antibodies.

Slide 70 · Five durable diagnostic lessons

Factor VIII is a cofactor for IXa-mediated factor X activation.

Residual activity largely explains clinical severity.

Hemarthrosis and deep hematomas suggest factor deficiency.

Normal PT plus prolonged PTT requires factor-specific confirmation.

A negative family history or normal factor VIII antigen cannot exclude disease.

Slide 71 · References and source boundary

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. (2026). Chapter 14: Hemophilia A, pp. 607–608.

Same textbook, Chapter 14: Coagulation-factor deficiencies and factor VIII–vWF complex, pp. 606–607.

Same textbook, Chapter 4: Normal hemostasis, coagulation and bleeding phenotypes, pp. 103–110.

FDA/DailyMed. Hemlibra (emicizumab) prescribing information (2025): bispecific binding to factor IXa and factor X.